BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
- About
-
- Email Address
- c.harrington@abdn.ac.uk
- Telephone Number
- +44 (0)1224 438563
- Office Address
Liberty Building, Institute of Medical Sciences, Foresterhill Road, Aberdeen AB25 2ZP United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.
The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.
Qualifications
- BSc (Hons) Microbiology1977 - University of Glasgow
- PhD Microbiology1980 - University of Glasgow
Latest Publications
LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy
European Journal of Pharmacology, 176505Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.ejphar.2024.176505
Apathy-like behaviour in tau mouse models of Alzheimer’s disease and frontotemporal dementia
Behavioural Brain Research, vol. 456, 114707Contributions to Journals: ArticlesA Meta-Analysis on Presynaptic Changes in Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 97, no. 1, pp. 145-162Contributions to Journals: ArticlesSolubility of α-synuclein species in the L62 mouse model of synucleinopathy
Scientific Reports, vol. 14, no. 6239Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/s41598-024-56735-6
Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
International Journal of Molecular Sciences, vol. 24, no. 18, 13747Contributions to Journals: Articles
- Research
-
Research Overview
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
- Publications
-
Page 2 of 10 Results 11 to 20 of 93
Glutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine
Cellular Signalling, vol. 97, 110386Contributions to Journals: ArticlesHMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine
Biomedicines, vol. 10, no. 4, 867Contributions to Journals: ArticlesHydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine
Journal of Neurochemistry, vol. 160, pp. 172-184Contributions to Journals: ArticlesDegeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia
Brain Communications, vol. 3, no. 4, fcab241Contributions to Journals: ArticlesLong-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrier
Journal of Alzheimer's Disease, vol. 83, no. 3, pp. 1017-1023Contributions to Journals: ArticlesProteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networks
Cells, vol. 10, no. 8, 2162Contributions to Journals: ArticlesTau Protein Phosphorylated at Threonine-231 Is Expressed Abundantly in the Cerebellum in Prion Encephalopathies
Journal of Alzheimer's Disease, vol. 81, no. 2, pp. 769-785Contributions to Journals: ArticlesElucidating the neuropathologic mechanisms of SARS-CoV-2 infection
Frontiers in Neurology, vol. 12, 660087Contributions to Journals: ArticlesInsoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer’s Disease Brains
International Journal of Molecular Sciences, vol. 22, no. 7, 3654Contributions to Journals: ArticlesOxidative Stress Conditions Result in Trapping of PHF-Core Tau (297–391) Intermediates
Cells, vol. 10, no. 3, 703Contributions to Journals: Articles